Tetraphase spikes on a Phase III success for lead antibiotic

John Carroll

Shares of Pharmaceuticals spiked 15% Wednesday afternoon after the biotech said its hit its primary endpoint in a head-to-head III study, leaving the company on track to file for an approval before the end of next year.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS